Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
08.07. | AQUAPORIN A/S: Reporting of transactions in financial instruments linked to Aquaporin's shares by persons discharging managerial responsibilities | 2 | Cision News | ||
07.07. | AQUAPORIN A/S: Aquaporin issues warrants under a new warrant program | 2 | Cision News | ||
20.06. | AQUAPORIN A/S: Reporting of transactions in financial instruments linked to Aquaporin's shares by persons closely associated with persons discharging managerial responsibilities in Aquaporin | 2 | Cision News | ||
AQUAPORIN Aktie jetzt für 0€ handeln | |||||
20.06. | AQUAPORIN A/S: Major shareholder announcement | 2 | Cision News | ||
12.06. | Aquaporin A/S: Aquaporin appoints Chief Executive Officer | 344 | PR Newswire | Company announcementNo. 09/2025
Inside information
Aquaporin A/SNymøllevej 78DK-2800 Kongens Lyngbyaquaporin.comCompany registration no.: DK28315694
KONGENS LYNGBY, Denmark... ► Artikel lesen | |
21.05. | Aquaporin A/S: Aquaporin Q1 2025 Trading Statement - maintains full-year financial guidance for 2025 | 266 | PR Newswire | Company announcementNo. 08/2025
Aquaporin A/SNymøllevej 78DK-2800 Kongens Lyngbyaquaporin.comCompany registration no.: DK28315694
KONGENS LYNGBY, Denmark , May 21, 2025 /PRNewswire/... ► Artikel lesen | |
15.05. | AQUAPORIN A/S: Aquaporin sells 500 CLEAR membranes to Chinese company CRZLO | 2 | Cision News | ||
08.05. | AQUAPORIN A/S: Aquaporin membranes to power projects in Chile and Mexico | 1 | Cision News | ||
01.05. | AQUAPORIN A/S: Aquaporin secures pilot plant contract for Trinity College Dublin at the IBF National Bioeconomy Campus | 5 | Cision News | ||
24.04. | Business transacted at the Annual General Meeting of Aquaporin A/S | 2 | Cision News | ||
11.04. | Aquaporin A/S - Admittance to trading and official listing of new shares due to exercise of warrants | 151 | GlobeNewswire | The share capital of Aquaporin A/S has been increased. The admittance of trading and official listing of new shares will take effect as per 14 April 2025 in the ISIN below.
ISIN:
DK0061555109
Name:
Aquaporin
Volume... ► Artikel lesen | |
02.04. | AQUAPORIN A/S: Notice convening the Annual General Meeting 2025 | 2 | Cision News | ||
01.04. | AQUAPORIN A/S: Aquaporin announces resignation by the CEO | 3 | Cision News | ||
28.03. | AQUAPORIN A/S: Aquaporin achieves breakthrough in the wine industry | 2 | Cision News | ||
21.03. | AQUAPORIN A/S: Aquaporin Inside® technology to enhance water management in Liaocheng | 1 | Cision News | ||
20.03. | Aquaporin A/S: Aquaporin announces full-year 2024 results | 510 | PR Newswire | Company announcementNo. 03/2025
Aquaporin A/SNymøllevej 78DK-2800 Kongens Lyngbyaquaporin.com Company registration no.: DK28315694
KONGENS LYNGBY, Denmark, March 20, 2025 /PRNewswire/... ► Artikel lesen | |
20.03. | Aquaporin A/S: Aquaporin announces guidance for 2025 | 114 | GlobeNewswire (Europe) | Company announcement
No. 02/2025
Inside information
Aquaporin A/S
Nymøllevej 78
DK-2800 Kongens Lyngby
aquaporin.com
Company registration no.: DK28315694
Kongens Lyngby, Denmark, March 20, 2025 -... ► Artikel lesen | |
12.03. | AQUAPORIN A/S: Aquaporin to host full-year 2024 results webcast on March 20 | 1 | Cision News | ||
26.02. | Aquaporin A/S: Aquaporin improves EBIT and specifies revenue guidance for 2024 | 120 | GlobeNewswire (Europe) | Company announcement
No. 01/2025
Inside information
Aquaporin A/S
Nymøllevej 78
DK-2800 Kongens Lyngby
aquaporin.com
Company registration no.: DK28315694
Kongens Lyngby, Denmark, February 26, 2025... ► Artikel lesen | |
14.11.24 | Aquaporin A/S: Aquaporin Q3 2024 Trading Statement | 542 | GlobeNewswire (Europe) | Company announcement
No. 19/2024
Aquaporin A/S
Nymøllevej 78
DK-2800 Kongens Lyngby
aquaporin.com
Company registration no.: DK28315694
Copenhagen, Denmark, November 14, 2024 - Aquaporin A/S (ticker:... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
QIAGEN | 41,405 | -0,35 % | Dividendenbekanntmachungen (10.07.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACCENTURE PLC IE00B4BNMY34 1,48 USD 1,2626 EUR AT&T INC US00206R1023 0,2775 USD 0,2367 EUR AZZ INC US0024741045 0,2 USD 0,1706... ► Artikel lesen | |
NUVALENT | 83,40 | -2,67 % | Nuvalent, Inc.: Nuvalent Announces Positive Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC | Aligned with FDA on NDA submission strategy for TKI pre-treated patients with advanced ROS1-positive NSCLC and participation in Real-Time Oncology Review; the... ► Artikel lesen | |
IMMUNOVANT | 17,910 | -2,02 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 | Immunovant's new management team is focused on rapid clinical execution for the six announced indications for IMVT-1402, including a second potentially registrational study in Graves' disease (GD)... ► Artikel lesen | |
EVOTEC | 7,456 | +0,59 % | Aixtron, Evotec, FMC, Redcare Pharmacy, Renk, ThyssenKrupp - Aktien-Positionen der Short-Seller | Wer Aktien leerverkauft, also auf fallende Kurse spekuliert (Shortselling), unterliegt bestimmten Transparenzpflichten. Aktuelle Meldungen über Leerverkäufe geben Aufschluss darüber. Diese Vorgaben... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 5,845 | +5,89 % | Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth? | ||
SUMMIT THERAPEUTICS | 26,200 | -5,18 % | Summit Therapeutics (SMMT) Climbs 16% Ahead of Q2 Earnings | ||
BIONTECH | 94,40 | -2,13 % | DAX-Korrektur! BioTech Im Übernahme-Modus! BioNTech, CureVac, Pfizer, Vidac Pharma und Kraft Heinz im Fokus | Die Aktienmärkte zeigen sich in Bestform: Sowohl der DAX als auch der NASDAQ 100 haben in den vergangenen Tagen Muskeln gezeigt. Angetrieben werden die Kurse vor allem von der anhaltenden Stärke der... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 33,740 | -0,88 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Positive Topline Phase 1/2 FORTITUDE Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in Del-Brax Treated FSHD Participants | -- Unprecedented data from FORTITUDE dose escalation cohorts for del-brax treated participants, compared to placebo, demonstrate improvement in function, strength and PROs as well as rapid... ► Artikel lesen | |
ARVINAS | 7,350 | -5,34 % | Arvinas Inc.: Arvinas Announces Retirement of Chief Executive Officer and Succession Plan | - John Houston, Ph.D., Chairperson, CEO and President at Arvinas, Announces Plans to Retire as CEO Upon Appointment of Successor - - Dr. Houston to Remain Chairperson of Arvinas Board of Directors... ► Artikel lesen | |
VERVE THERAPEUTICS | 10,915 | -0,32 % | Verve Therapeutics sichert Führungskräfte mit Halteprämien vor Übernahme durch Eli Lilly | ||
TELOMIR PHARMACEUTICALS | 2,300 | +90,08 % | Telomir Pharmaceuticals, Inc: Telomir Demonstrates Telomir-1 Reverses Epigenetic Gene Silencing of STAT1, Restoring Tumor Suppressor in Human Prostate Cancer Cells, Outperforming Chemotherapy and Rapamycin | New data shows Telomir-1 fully reverses STAT1 gene silencing by DNA methylation - a key immune regulator suppressed in cancer - delivering stronger epigenetic effects than Paclitaxel or Rapamycin in... ► Artikel lesen | |
ADMA BIOLOGICS | 16,730 | -4,89 % | ADMA Biologics, Inc.: ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update | 1Q 2025 Total Revenue of $114.8 Million (Adjusted Total Revenue(1) of $118.6 Million), a 40% YoY Increase 1Q 2025 GAAP Net Income of $26.9 Million, a 51% YoY Increase 1Q 2025 Adjusted EBITDA(2) of... ► Artikel lesen | |
SAREPTA THERAPEUTICS | 12,080 | -0,29 % | Sarepta Therapeutics-Aktie +35%: Ist das die Wende? | Die Kursentwicklung der Sarepta Therapeutics -Aktie trieb Anlegern in jüngster Vergangenheit nur die Tränen in die Augen. In den letzten zwölf Monaten lösten sich fast -90% des Börsenwerts des Biotech-Unternehmens... ► Artikel lesen | |
COGENT BIOSCIENCES | 12,500 | +2,29 % | Cogent Biosciences auf Rekordhoch: Positive Studienergebnisse und Kapitalerhöhung beflügeln Kurs | ||
CRISPR THERAPEUTICS | 56,00 | 0,00 % | AKTIONÄR-Depotwert CRISPR Therapeutics: Aktie kommt in Fahrt - jetzt noch kaufen? | Die Aktie des AKTIONÄR-Depotwerts CRISPR Therapeutics hat sich in den vergangenen Wochen enorm stark entwickelt. Zuletzt hat sich die Aufwärtsbewegung sogar noch einmal beschleunigt. Seit dem Tief Anfang... ► Artikel lesen |